Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | BRAF | P15056 | 17/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592952 | 0.91 | BRAF (0.62) | PKMBRAFNPSR1 | |
| SCHEMBL3594537 | 0.89 | PKM (0.63) | PKMBRAFMEN1HSP90AA1KMT2A | |
| SCHEMBL3595376 | 0.84 | PKM (0.57) | PKMBRAFMEN1HSP90AA1KMT2A | |
| SCHEMBL3593583 | 0.82 | PKM (0.64) | PKMBRAFNPSR1 | |
| SCHEMBL3601159 | 0.79 | PKM (0.59) | PKMBRAF | |
| SCHEMBL3594488 | 0.78 | BRAF (0.64) | PKMBRAFNPSR1 | |
| SCHEMBL3589989 | 0.78 | BRAF (0.66) | PKMBRAFNPSR1 | |
| SCHEMBL14138688 | 0.77 | PKM (0.79) | PKMBRAFRAF1 | |
| SCHEMBL28020452 | 0.76 | EGFR (0.77) | MEN1KMT2A | |
| SCHEMBL3588600 | 0.75 | BRAF (0.55) | PKMBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MAP3K5, MAP4K5, MAP3K20 | PKM 315/4885BRAF 123/4885MEN1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.